CVKD CFO reports Rule 10b5-1 stock sales at ~$14 per share

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO sold 1,693 shares of common stock at $13.99, and on 10/13/2025, sold 1,800 shares at $14.07, in each case under a Rule 10b5-1 trading arrangement. Following these sales, the CFO directly beneficially owned 13,533 shares.

Insider Trade Summary

Net Seller: 3,493 shares

Net Sell 2 txns

Insider Szot Matthew K

Role Chief Financial Officer

Sold 3,493 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,800	$14.07	$25K
Sale	Common Stock	1,693	$13.99	$24K

Holdings After Transaction: Common Stock — 13,533 shares (Direct)

Footnotes (1)

1. F1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement.

FAQ

What did Cadrenal Therapeutics (CVKD) disclose in this Form 4?

The CFO reported sales of common stock on 10/09/2025 and 10/13/2025 under a Rule 10b5-1 trading plan.

How many CVKD shares did the CFO sell and at what prices?

1,693 shares at $13.99 on 10/09/2025 and 1,800 shares at $14.07 on 10/13/2025.

How many CVKD shares does the CFO hold after the transactions?

The filing lists 13,533 shares directly beneficially owned after the reported transactions.

Was the sale made under a pre-arranged plan?

Yes. The filing states the sales were made in accordance with a Rule 10b5-1 trading arrangement.

What is the reporting person’s role at Cadrenal Therapeutics?

Officer—Chief Financial Officer.

What is the ownership form reported for the remaining shares?

Direct (D) ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/14/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Szot Matthew K

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA, FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S		1,693	D	$13.99(1)	15,333	D
Common Stock	10/13/2025		S		1,800	D	$14.07(1)	13,533	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement.

	/s/ Matthew K. Szot	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.